Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=30279688&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Taurodeoxycholate Increases the Number of Myeloid-Derived Suppressor Cells That Ameliorate Sepsis in Mice #MMPMID30279688
Chang S; Kim YH; Kim YJ; Kim YW; Moon S; Lee YY; Jung JS; Kim Y; Jung HE; Kim TJ; Cheong TC; Moon HJ; Cho JA; Kim HR; Han D; Na Y; Seok SH; Cho NH; Lee HC; Nam EH; Cho H; Choi M; Minato N; Seong SY
Front Immunol 2018[]; 9 (?): 1984 PMID30279688show ga
Bile acids (BAs) control metabolism and inflammation by interacting with several receptors. Here, we report that intravenous infusion of taurodeoxycholate (TDCA) decreases serum pro-inflammatory cytokines, normalizes hypotension, protects against renal injury, and prolongs mouse survival during sepsis. TDCA increases the number of granulocytic myeloid-derived suppressor cells (MDSC(LT)) distinctive from MDSCs obtained without TDCA treatment (MDSC(L)) in the spleen of septic mice. FACS-sorted MDSC(LT) cells suppress T-cell proliferation and confer protection against sepsis when adoptively transferred better than MDSC(L). Proteogenomic analysis indicated that TDCA controls chromatin silencing, alternative splicing, and translation of the immune proteome of MDSC(LT), which increases the expression of anti-inflammatory molecules such as oncostatin, lactoferrin and CD244. TDCA also decreases the expression of pro-inflammatory molecules such as neutrophil elastase. These findings suggest that TDCA globally edits the proteome to increase the number of MDSC(LT) cells and affect their immune-regulatory functions to resolve systemic inflammation during sepsis.
free
free
free
Front+Immunol 2018 ; 9 (?): 1984
